Daniel Yokell
VP of Theranostic NeuroOncology Telix Pharmaceuticals
Wednesday 16th September 2026
Bridging the Inflection Point from Early Development to Late-Stage Manufacturing to Support Phase II/III Expansion
12:00 pm
- Transitioning from low-volume, flexible production to high-throughput, standardized manufacturing systems
- Scaling batch sizes while maintaining product quality, consistency, and regulatory compliance
- Identifying infrastructure, equipment, and workforce requirements for late-stage trials
- Mitigating risks associated with rapid scale-up and increasing demand
Thursday 17th September 2026
Panel Discussion: Future Directions – Where Does the Chain Break? A Collective Assessment of the Industry’s Most Critical Unresolved Supply Chain Challenges & the Priorities That Must Be Addressed Collectively Before the Next Wave of Approvals Arrives
4:00 pm
- Across the two days, which single supply chain or manufacturing bottleneck has emerged as most urgent, and what does a credible industry-level response to it look like?
- Where does the field realistically stand on isotope supply security in five years, and which production pathways, technologies, and investment models will determine whether commercial-scale alpha therapy becomes a reality?
- How must the relationship between biopharma, CDMOs, isotope providers, logistics specialists, and clinical sites evolve structurally to one that can reliably deliver therapies to patients at scale?
